HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bosentan

HCID 104865
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
147536-97-8
Standard SMILES
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO
InChIKey
GJPICJJJRGTNOD-UHFFFAOYSA-N
Molecular formula
C27H29N5O6S
Average molar mass
551.6 g/mol
Monoisotopic mass
551.18385484

Overview

Bosentan is a primary alcohol, a sulfonamide and a member of pyrimidines. It has a role as an antihypertensive agent and an endothelin receptor antagonist.

Names & identifiers

Preferred name
Bosentan
IUPAC
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
English name
Bosentan
Molecular formula
C27H29N5O6S
Molecular weight
551.61

Names & synonyms

Bosentan147536-97-8Tracleerbosentan anhydrousbosentanumRo 47-0203Anhydrous bosentanRo-47-02034-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamideDTXSID7046627p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamideRo-47-0203/029
Show more names
Bosentan impurityBosentan USP/EP/BPActelionro47-0203ro47-0203/039Bosentan 13C6Bosentan - Bio-X ?bosentan , CID 104865Bosentan, 10 mM in DMSO
XUL93R30K24-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamideBenzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-DTXCID5026627CHEBI:514504-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamideBenzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-Ro-470203029

Properties

Computed structural properties

XLogP
3.8
Topological polar surface area
154 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
11
Rotatable bonds
11
Heavy atoms
39
Formal charge
0
Complexity
839

Experimental & physicochemical properties

Drugs · 3 items

Pharmaceuticals

Pharmaceuticals -> Antihypertensives

Pharmaceuticals -> Listed in ZINC15

LogP · 2 items

3.7

1.99

Solubility · 2 items

Poorly soluble in water (1.0 mg/100 ml) and in aqueous solutions at low pH (0.1 mg/100 ml at pH 1.1 and 4.0; 0.2 mg/100 ml at pH 5.0). Solubility increases at higher pH values (43 mg/100 ml at pH 7.5).

9.04e-03 g/L

Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Cardiovascular Agents; Endothelin Receptor Antagonists; Vasodilator Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physical DescriptionSolid
Collision Cross Section229.9 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID80873178]

Physicochemical properties

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H302 (40%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P273, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (40%)

Toxicology

Hepatotoxicity · 1 item

Bosentan is associated with elevations in serum aminotransferase levels above three times the upper limit of the normal range (ULN) in 3% to 18% of patients, averaging 7.6% using currently recommended doses. The enzyme elevations are usually self-limited and are rarely accompanied by symptoms, but can be more marked and persist and require dose reduction or discontinuation (in 3% to 4% of patients). Monthly monitoring of serum aminotransferase levels is recommended, with discontinuation for levels above 8 times the ULN or for values above 5 times the ULN that persist. There have also been rare reports of clinically apparent liver injury with jaundice associated with bosentan use. The onset of illness was usually within 1 to 6 months of starting bosentan, but cases arising during chronic therapy have also been described (Case 1). The enzyme pattern has typically been hepatocellular or mixed. Immunoallergic features are usually not present and autoantibodies are usually absent or present in low titer. Some cases have been severe and fatalities have been reported, but there have been no published reports of chronic hepatitis or vanishing bile duct syndrome attributed to bosentan. Autoimmune and immunoallergic features are usually not present.

Chemistry & industry

Pharmacology

ATC Code · 3 items

C02KX01

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingGreater than 98% to plasma proteins, mainly albumin.
Pharmacodynamics · 1 item

Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.

Mechanism of Action · 1 item

Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ET<sub>A</sub> and ET<sub>B</sub> receptors in the endothelium and vascular smooth muscle. It displays a slightly higher affinity towards ET<sub>A</sub> receptors than ET<sub>B</sub> receptors. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ET<sub>A</sub> and ET<sub>B</sub>.

Biological Half-LifeTerminal elimination half-life is about 5 hours in healthy adult subjects.
Metabolism/Metabolites · 2 items

Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.

Bosentan has known human metabolites that include 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2-]bipyrimidinyl-4-yl]-benzenesulfonamide and Hydroxy Bosentan.

FDA Pharmacological Classification · 6 items

XUL93R30K2

BOSENTAN ANHYDROUS

Established Pharmacologic Class [EPC] - Endothelin Receptor Antagonist

Related reactions

16 records
New reaction record
HRID 97752 reaction equation
HRID 97752As product
HRID 397262 reaction equation
HRID 397262As reactant
HRID 448549 reaction equation
HRID 448549As product
HRID 448550 reaction equation
HRID 448550As product
HRID 448551 reaction equation
HRID 448551As product
HRID 954007 reaction equation
HRID 954007As product
HRID 1020775 reaction equation
HRID 1020775As product
HRID 1020776 reaction equation
HRID 1020776As product
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
147536-97-8
PubChem CID
104865
DTXSID
DTXSID7046627
ChEMBL
CHEMBL957
ChEBI
CHEBI:51450
UNII
XUL93R30K2
EC Number
643-099-1
Nikkaji
J594.472D
Melting point
107 · 107-110°C
Boiling point
742.3 · 742.3±70.0 °C(Predicted)
Density
1.325 · 1.325±0.06 g/cm3(Predicted)
storage temp.
-20 °C · -20°C Freezer
solubility
DMSO (Slightly), Methanol (Slightly)
form
Solid
pka
4.01 · 4.01±0.10(Predicted)
color
White to Pale Yelloow
CAS DataBase Reference
147536 · 147536-97-8(CAS DataBase Reference)
FDA UNII
93 R30K2 · XUL93R30K2
ATC code
2 KX01 · C02KX01
Comptox DTXSID
7046627 · DTXSID7046627
Protein binding
98 % · >98%
Excreted unchanged in urine
3 % · <3%
Volume of distribution
18 Litres · 18 Litres
Biological half-life
5 · 5-8 / Unchanged
Symbol(GHS)
7 · GHS07,GHS08,GHS09
Signal word
Danger
Hazard statements
302 · H302-H360-H410
Precautionary statements
273 · P273-P281
HS Code
29350090 · 29350090
Adverse Effects
Safety Profile
Toxicity Summary · 1 item

The most frequently observed adverse effect of bosentan overdose is headache. In a cyclosporine A interaction study, administration of 500 mg and 1,000 mg of bosentan twice daily in combination with cyclosporine A resulted in a 30-fold increase in trough plasma concentrations, leading to severe headache, nausea, and vomiting. No serious adverse events were reported. Additional findings included hypotension and tachycardia.

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Bosentan

vMost-DILI-concern

7

Box warning

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

hs_code
29350090
Signal word
Danger
Symbol(GHS)
GHS07,GHS08,GHS09
Hazard statements
H302-H360-H410
Precautionary statements
P273-P281

Mechanisms of Action [MoA] - Endothelin Receptor Antagonists

Mechanisms of Action [MoA] - Cytochrome P450 3A Inducers

Mechanisms of Action [MoA] - Cytochrome P450 2C9 Inducers

MeSH Pharmacological Classification · 2 items

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS.

Absorption, Distribution and Excretion · 4 items

Absolute bioavailability is approximately 50% and food does not affect absorption.

Bosentan is eliminated by biliary excretion following metabolism in the liver.

18 L

4 L/h [patients with pulmonary arterial hypertension]

Cellular LocationsMembrane

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >100
Applications · 4 items

DescriptionBosentan was introduced in the US as a twice-daily oral treatment for pulmonary arterial hypertension. It can be synthesized in five steps via condensation of diethyl (2- methoxyphenoxy)malonate with pyrimidine-2-carboxamidine to give the precursor of the symmetrical central dichloropyrimidine ring which is then successively treated with the potassium salt of 4-tert-butylbenzenesulfonamide and the sodium salt of ethylene gycol. Bosentan is the first endothelin (ET) receptor antagonist to be launched. ET-1, the most potent endogenous vasoconstrictor known, has been demonstrated to play a major role in the functional and structural changes observed in pulmonary hypertension. Bosentan is a mixed ETA and ETB receptor antagonist that inhibits the pulmonary arterial vasoconstricting effect of ET-1 predominantly mediated via ETA receptors on smooth muscle cells. In a hypoxia-induced model of pulmonary hypertension in rat, it reduced the development of pulmonary hypertension as well as right ventricular hypertrophy and prevented pulmonary arterial remodeling. In clinical trials, patients treated with bosentan showed a 20% increase in exercise capacity compared to placebo as measured by the six minute walk test. Bosentan not only improved the distance walked by patients but also significantly decreased mean pulmonary artery pressure, mean pulmonary vascular resistance, mean capillary wedge pressure and mean right atrial pressure. It demonstrated a beneficial selectivity for the pulmonary vasculature since it had no significant effect on mean aortic blood pressure and systolic vascular resistance. The compound is hepatically metabolized into three major metabolites by CYP3A4 and 2C9 and almost exclusively eliminated in the bile. Although large interspecies differences in systemic plasma clearance was observed (1.5 mL/min/kg in dogs to 72 mL/min/kg in rabbits), a satisfactory systemic clearance (2 mL/min/kg) was measured in human. The most frequent adverse effect was reversible elevation of liver transaminases. This adverse reaction appears to be due to intracellular accumulation of cytotoxic bile salts resulting from inhibition of the hepatocanalicular bile salt export pump by bosentan.

UsesBosentan is a mixed endothelin receptor antagonist. Used as a vasodilator. Antihypertensive.

UsesA mixed endothelin receptor antagonist. Used as a vasodilator. Antihypertensive.

General DescriptionBosentan, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tertbutyl-benzenesulfonamide (Tracleer, Bozentan), was thefirst endothelin receptor antagonist marketed in the UnitedStates. Bosentan works by competitively blocking the endothelinreceptor subtypes ETA and ETB. In binding to thereceptors, it blocks the effects of endothelin, which includeconstriction of the vascular smooth muscle, which leads tonarrowing of the blood vessels and hypertension. Althoughit is not selective for the ETA receptors, it does have a higheraffinity for that subtype over ETB. However, the clinical significanceof selectivity over preferential receptor bindinghas not been demonstrated. Bosentan is an inducer ofCYP2C9 and CYP3A4, and patients using bosentan must bemonitored for liver toxicity.

Upstream & downstream products

Upstream raw materials

L(+)-Tartaric acidEthylene glycolbeta-(4-Chlorophenyl)glutaric anhydrideSodium2-Amidinopyrimidine hydrochloride4,6-Dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidineD-(-)-Tartaric Acid2-(2-Methoxyphenoxy)propanedioic acid diethyl ester

Additional notes

DefinitionChEBI: Bosentan is a sulfonamide, a member of pyrimidines and a primary alcohol. It has a role as an antihypertensive agent and an endothelin receptor antagonist.